TrialPivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Trial details
- Registry ID
- NCT02831959
- Phase
- Phase 3
NVCR
NovoCure GmbH
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
9Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceEffect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
Trial details
- Registry ID
- NCT02973789
- Phase
- Phase 3
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
Trial details
- Registry ID
- NCT04492163
- Phase
- Phase 2
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Trial details
- Registry ID
- NCT04892472
- Phase
- Phase 2
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Trial details
- Registry ID
- NCT06216301
- Phase
- Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Trial details
- Registry ID
- NCT06556563
- Phase
- Phase 3
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
Trial details
- Registry ID
- NCT06558799
- Phase
- Phase 2
Latest recorded trial changes
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT06558799 · NovoCure GmbH
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
69 participants (planned)
+ After
31 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
31 Jan 2026
+ After
23 Feb 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Terminated
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NCT02973789 · NovoCure GmbH
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Overall survival of patients treated with TTFields + docetaxel or immune checkpoint inhibitors vs. docetaxel or immune checkpoint inhibitors alone (superiority analysis)
+ After
Measure: Overall Survival of Patients Treated With TTFields + Docetaxel or Immune Checkpoint Inhibitors vs. Docetaxel or Immune Checkpoint Inhibitors Alone (Superiority Analysis)
Actual enrollment increased by 15 participants
− Before
276 participants (actual)
+ After
291 participants (actual)
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT06558799 · NovoCure GmbH
Primary completion date changed
− Before
Dec 2026
+ After
31 Jan 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting